Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They supplied a piece in
one of the last two studies, the rectal or vaginal study
I only see the one mil change in the float that Siar mentioned
later
Funding: This work was supported by National Institutes of Health (NIH/NIAID/ DAIDS): Center for HIV/AIDS Vaccine Immunology Grant (U01 AI067854) and the Collaboration for AIDS Vaccine Discovery Grants from the Bill and Melinda Gates Foundation (1033098), the NIH/NIAID Reagent Resource Support Program for AIDS Vaccine Development (Quality Biological, Inc.), Contract HHSN272201100023C, Immunology Virology Quality Assessment (IVQA) Center Laboratory Shared Resource, and the NIH grant AI097315. Crystallography was performed in the Duke University X-ray Crystallography Shared Resource. Use of the Advanced Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. W-31-109-Eng-38. SER-CAT supporting institutions may be found at www.ser-cat.org/members.html. The views expressed in this manuscript are those of the authors and do not represent the official views of the Department of the Army or the Department of Defense. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005042
https://www.qualitybiological.com/about/
https://www.crunchbase.com/organization/quality-biological
https://scholars.duke.edu/display/insqualitybiologicalinc
https://www.dnb.com/business-directory/company-profiles.quality_biological_inc.21e6d6ede9c56b64527ddb78a136abf7.html
https://www.sbir.gov/sbc/quality-biological-inc
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
https://pubmed.ncbi.nlm.nih.gov/27028935/
Kshitij Wagh PhD
Los Alamos National Laboratory
https://virtual.keystonesymposia.org/ks/speakers/view/8
https://physics.rutgers.edu/news/news-archive/2019-news/former-graduate-student-kshitij-wagh-who-got-his-phd-in-2013-under-the-direction-of-prof-gyan-bhanot-has-made-important-progress-in-understanding-new-approaches-towards-hiv-vaccine-design
U.S. Department of Energy
Office of Scientific and Technical Information
https://www.osti.gov/biblio/1245848-human-non-neutralizing-hiv-envelope-monoclonal-antibodies-limit-number-founder-viruses-during-shiv-mucosal-infection-rhesus-macaques
Several of Korber’s vaccine designs have transitioned to the commercial sector. Janssen, a subsidiary of Johnson & Johnson, is testing one of her designs, called “mosaic,” in a clinical trial called the Imbokodo Study, being conducted in South Africa. If successful, the vaccine could be one of the first to prevent the HIV infection.
Biotechnology company VIR is also testing another HIV vaccine design in monkeys that have the simian immunodeficiency virus (SIV), the counterpart to HIV.
Let's hear if for Cal Tech, the DOD & DOE
https://www.lanl.gov/discover/news-release-archive/2021/February/0209-la-medal.php
Two Los Alamos Medal winners recognized for revolutionary contributions
Korber’s response to the COVID-19 pandemic has been immediate and impactful. She led a team of Los Alamos scientists that rapidly developed a computational pipeline to automatically process and analyze the hundreds of thousands of SARS-CoV-2 sequences submitted by international investigators to GISAID. A global database, GISAID provides open access to genomic data of the virus responsible for the COVID-19 pandemic. Using these data, Korber and her team identified a mutated form of the virus that was more readily transmitted than the ancestral from; this variant rapidly became the most dominant form worldwide.
https://www.nih.gov/research-training/medical-research-initiatives/activ/trace-working-group
Really surprised RK isn't on that one so he should continue to promote himself LOL
Bette Korber
She created a database at Los Alamos National Laboratory that has enabled her to design novel mosaic HIV vaccines
Korber oversees the HIV Database and Analysis Project at Los Alamos.
https://en.wikipedia.org/wiki/Bette_Korber
Promising Los Alamos Innovations Take the Spotlight
Bette Korber receives 2018 Richard P. Feynman Innovation Prize for HIV vaccine designs
https://www.newswise.com/articles/promising-los-alamos-innovations-take-the-spotlight-
S. Munir Alam, PhD
https://medicine.duke.edu/faculty/s-munir-alam-phd
https://dhvi.duke.edu/alam-s-munir
https://www.cavd.org/Pages/EarlyInvestigator2010.aspx
New Insight on Potent HIV Antibody Could Improve Vaccine Design
https://corporate.dukehealth.org/news/new-insight-potent-hiv-antibody-could-improve-vaccine-design
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523205/
If you took the mrna vac you may have Hiv
lol ?
https://strangesounds.org/2022/02/the-msm-prepares-the-public-for-incoming-aids-outbreak-covid-vaccine-link.html
https://en.wikipedia.org/wiki/Luc_Montagnier
Bill Gates says HIV Vaccines will be a Reality by 2030!
https://goldenicons.com/bill-gates-says-hiv-vaccines-will-be-a-reality-by-2030/
Bill Gates says Covid risks have ‘dramatically reduced’ but another pandemic is coming
https://www.cnbc.com/2022/02/18/bill-gates-covid-risks-have-reduced-but-another-pandemic-will-come.html
How could he know that, he's a paranoid that can see into the future lol or does he want one ?
We should have Texas Pete chase this all day & night for months on end
LOL
Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses
06 April 2022
Weill Cornell
https://journals.asm.org/doi/10.1128/jvi.00034-22#body-ref-B175
175 Citation
HIV-1 HxB2 gp41 peptides coupled to virosomes IM x 4 or IM x 2 then IN x 2
SHIV-SF162P3 20-30 TCID50 13 iterations IV
https://pubmed.ncbi.nlm.nih.gov/21315623/
https://investorshub.advfn.com/boards/replies.aspx?msg=168074399
Why are the publications for U19AI142636 not there now ?
https://reporter.nih.gov/search/3Izo_XkpFEeXsJiksUCkXw/publications
By googlie does Google, Gates, the Nih & the Swiss ever have it bad. Totally ate up w/ it. NO ONE CARES
LOL
Judge rules US military can't discharge HIV-positive troops
What did Ronnie's wife do ?
https://www.yahoo.com/news/judge-rules-us-military-cant-215619779.html
RICHMOND, Va
Sole owner of Black Eye of Biopole still owns that
& I don't care about it
:}
Ms Bertarelli, 50, is now living alone in a breathtaking £52 million mansion on the shores of Lake Geneva. She was awarded it as part of a £400 million divorce settlement that makes her the richest British-born divorcee in history, with a fortune exceeding that of the Queen and J. K. Rowling.
https://www.dailymail.co.uk/news/article-10070767/Kirsty-Bertarelli-UK-beauty-queen-billionaires-wife.html
La Villa Tatiana, société anonyme, Villa, Switzerland
https://www.northdata.com/La+Villa+Tatiana,+soci%C3%A9t%C3%A9+anonyme,+Crans-pr%C3%A8s-C%C3%A9ligny/CHE-101.418.727
https://business-monitor.ch/en/p/frederic-boder-3449921
Let's hear it for Umbrella Ag
Viva Lukas
LOL
He sits on the strategic advisory board of the Swiss school.
https://www.superyachtfan.com/yacht/vava-ii/owner/
Nice finds, my is that ever close to RK in Dully
:}
https://opencorporates.com/companies/ch/202320
& the beauty of maybe finally having a success that was so double double triple triple secret to promote Biopole in the end is that no one cares
LOL
Very nice ty
As always the to & replies
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167605024
Mymx & MRC Harwell
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167065167
Ronald Kempers (1) CEO, CFO and Director
Pg 4
https://www.sec.gov/Archives/edgar/data/927761/000114036113027769/form10ka.htm
Interesting what is says as a group
Anergis Closes CHF 18 Million Series A Financing Round to develop its Innovative Allergy Vaccines
The syndicate was also joined by Esperante (Limhamn, Sweden), Initiative Capital Romandie (Lausanne, Switzerland) and by private investors. Up until now
About Initiative Capital Romandie (ICR):
ICR is a Swiss venture capital fund, managed by DEFI Gestion SA, a Lausanne based private equity funds advisor. ICR has been founded in 2006 by four partners (Retraites Populaires Vie, Banque Cantonale Vaudoise, Centre Patronal and Etablissement Cantonal d’Assurance). ICR supports high-tech starts-ups based in the French speaking part of
https://www.startupticker.ch/en/news/anergis-closes-chf-18-million-series-a-financing-r
Novartis muscles in again on NanoPowers round
Jun 2, 2010 • James Mawson
Novartis Venture Funds leads first round of funding for NanoPowers
Novartis Venture Funds, the $750m corporate venturing division of pharmaceutical firm Novartis, has led a SWF5m ($4.5m) first round of funding for NanoPowers, a Switzerland-based medical device company that makes artificial muscles. Initiative Capital Romandie, a SWF15m VC fund run by Switzerland’s DEFI Gestion private equity group and which last invested in Endosense last year,…
https://globalventuring.com/corporate/novartis-muscles-in-again-on-nanopowers-round/
DEFI Gestion Employee Profiles
management buy-out of DEFI Gestion and became apartner in connection with the launch of the venture capital fund Initiative Capital Romandie and the fund DEFI EuroCap III.
began his career at Nestlé Research Center in research anddevelopment, then successively worked for ACM (organizing body of the America's Cup in Valencia)
He is a partner of DEFI Holding SA, VDCapital and DEFI EuroCap III.
https://www.crunchbase.com/organization/defi-gestion/people
including Novartis Venture Funds , Gran Plasa SA and Initiative Capital Romandieparticipated in this fundraising campaign.
https://www-businesswire-com.translate.goog/news/home/20110705006104/fr/?_x_tr_sl=fr&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Financial Arbevel
Taken over by its current managers at the end of 2008,
Gestion collective ?
https://funds360-euronext-com.translate.goog/acteur/societe-de-gestion/financiere-arbevel?_x_tr_sl=fr&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
Initiative Capital Romandie SA en liquidation
https://business-monitor.ch/en/companies/341514-initiative-capital-romandie-sa-en-liquidation/contacts
From that
PM ?
https://business-monitor.ch/en/list-builder?filters%5Bmunicipality_number%5D%5B%5D=6458
https://business-monitor.ch/en/companies/140149-philip-morris-products-s-a
Leading French business daily Les Echos publishes op-ed co-authored by 12 BSP signatories
Marc Le Bozec (Fund Manager at Financière Arbevel)
https://biotechsocialpact.com/leading-french-business-daily-les-echos-publishes-op-ed-co-authored-by-12-bsp-signatories/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162195523
https://finance.yahoo.com/quote/0P0001LAG1.F/purchase-info/
Gee lol
Nice snag, Philips Care
?
https://biotechsocialpact.com/
https://www.fiercebiotech.com/medtech/philips-to-bring-spencer-health-s-digital-pill-hub-to-europe
https://www.philips.com/a-w/about/news/archive/standard/news/articles/2021/20210608-artificial-intelligence-can-revolutionize-innovation-in-healthcare.html
More of RK & JB
https://biotechsocialpact.com/the-pact/
Thanks for the list
of potential future female marriage suitors
for Ernesto that is
ROTFLOL
Nasri Nahas
Geneva, Geneva, Switzerland
Chief Executive Officer
Biopôle SA
https://ch.linkedin.com/in/nasrinahas
https://rocketreach.co/nasri-nahas-email_62068293
10 years of Biopôle by Nasri Nahas
https://www.biopole.ch/10-years-of-biopole-by-nasri-nahas/
Biopôle Lausanne
https://twitter.com/biopolelausanne
@Philips
https://twitter.com/Philips
https://twitter.com/PhilipsCare
https://www.philips.com/a-w/about.html
Koninklijke Philips N.V
https://en.wikipedia.org/wiki/Philips
Samantha Brandler
The main focus of Samantha’s research was on vaccine development and during that time she co-invented the most advanced chikungunya vaccine, now in phase 3 clinical trials, licensed to Themis Bioscience and recently acquired by Merck MSD.
https://www.biopole.ch/story/how-do-start-ups-support-biopoles-partners/
Stéphanie Boue
Philip Morris International
https://www.biopole.ch/event/biopole-qa-data-visualization-and-scientific-illustration/
https://www.crunchbase.com/person/st%C3%A9phanie-boue
today announced that its Board of Directors has named Jacques-François Martin as Chairman of the Board, President and CEO, effective July 1, 2009, replacing Christian Rochet who remains as a non executive Director.
Since gone but you get Siar's drift if a change for RK
https://www.sec.gov/Archives/edgar/data/927761/000095012309017317/l36886aexv99w1.htm
The money hunt
wasn't me
:}
WAYPOINT (JERSEY) LIMITED
https://opencorporates.com/companies/je/EXTUID_106843
Alinghi holding on at GC32 Riva Cup
Published on September 14th, 2019
Riva del Garda, Italy (September 14, 2019) – Ernesto Bertarelli’s Alinghi started the day four points ahead of Oman Air and – after six races on two different courses, during which they lost the lead, then fought back hard to recover it – ended the day four points ahead of Oman Air.
https://www.sailingscuttlebutt.com/2019/09/14/alinghi-holding-on-at-gc32-riva-cup/
I see that Dynamics Group is involved w/ The Finical Times. It they who sent you to get your directors cert for Biopole I take it.
How about that otc cert Mr K
BDO also slaps Kempers down
LOL
Christophe Lamps
Senior Partner, Dynamics Group
Focus on corporate, media and investor relations in a number of fields, including primarily the life sciences, banking, public services and academia.
In an agency setting, extensive work with a large number of Swiss and international companies. These include companies such as Logitech, Microsoft or Pfizer as well as banks, including Morgan Stanley, and Swiss private banks. Worked for Alinghi Holding and America’s Cup Management. Involved in a number of IPO's such as Cytos Biotechnology, Addex, BioXell and Givaudan on the Swiss Stock Exchange.
Handling communications activities and media relations in Europe for the Bill & Melinda Gates Foundation. He is also one of the founders and organizers of BioData, the yearly Swiss and international biotechnology symposium, and of the Geneva Lake Innovation Society.
Before joining Dynamics Group Christophe was partner at a Geneva based communications agency and for ten years Head of Corporate Communications, Corporate Affairs and Investors Relations, as well as spokesman, of Serono, Europe’s largest biotechnology companies. During this time, he also served as a member of the Board of Interpharma (Novartis, Roche and Serono) and of the Swiss Association of Biotechnology Companies.
After receiving a Bachelor's degree from the Graduate Institute of International Studies (Geneva), and a Master's degree (MALD) from the Fletcher School of Law and Diplomacy (Boston), started working for the World Economic Forum, taking part in the organisation of the Davos Symposium.
In 1984 joined Hill & Knowlton, a leading international public relations counseling firm, at their European headquarters in Geneva, before being called to Paris, to manage the agency until 1989.
Fluent in English, French and German.
He is a Political Scientist
LOL
https://ch.linkedin.com/in/christophe-lamps-a4a47b8?challengeId=AQFaKi4RqGfRhwAAAX_6HgkeQfK7sG4-6M3FUTQ2tNyfpLV8O4gmSWUAegBPoqePWJjb_SQVQLZK6yc0eSt50eo2SOaQBzxn2g&submissionId=18fd1dbe-3c06-e316-6d70-6ebb40bf1040
Fella to the right you have something in common with
Thierry Meyer
Senior Partner, Dynamics Group SA
Relations Manager, Lausanne Hockey Club
I wonder if he knows anything about talent
LOL
Wish I knew
makes no sense to anyone
later
Fear LOL eom
Very nice snag Ph, thanks again
Ernest Stern’s Corporate and Securities practice includes the representation of public and private emerging companies, many of which are technology based. Ernest assists these clients in their growth plan starting with their formation in the appropriate form of entity, a capital structure to accommodate growth, shareholder agreements and stock option plans, assisting them with financings to accelerate their growth through venture financing in the form of private placements with high net worth individuals or Angel financing, institutional venture capital, crowd funding, PIPE investments, Regulation A+ financings, IPOs and reverse mergers. He also represents venture capital firms in their investments in early-stage companies.
Additionally, he advises companies in domestic and cross-border mergers and acquisitions of public and private companies and has extensive experience in advising on SEC and FINRA compliance issues having served as General Counsel and compliance officer of a FINRA registered broker/dealer. Ernest handles all filings of public companies under the SEC rules and regulations under federal securities laws.
https://www.culhanemeadows.com/attorney/ernest-m-stern/
Recently, Ernest handled one of the first 20 confidential IPO filings under the JOBS Act for an emerging growth company and served as underwriters’ counsel for a successful IPO of a company that listed on NASDAQ. Additionally, he advises companies in cross-border and domestic mergers and acquisitions, and he has extensive experience in advising on SEC and NASD compliance issues.
https://lawtally.com/lawyers/ernest-stern/
and overseas mergers and acquisitions transactions. He represents hedge funds, publicly traded companies and emerging companies as well as various brokers/dealers and investment advisers.
https://www.seyfarth.com/news-insights/corporate-attorney-ernest-m-stern-joins-seyfarth-shaw-s-washington-d-c-office.html
Dist. of Columbia Mergers and acquisitions lawyers
Licensed for 46 years
https://www.avvo.com/mergers-acquisitions-lawyer/dc.html?page=8
Bureaucracy is my Kryptonite & something tells me there is a healthy dose headed my way, hopefully that it isn't Mymx related but
Spokane maybe
LOL
We'll see what kinda interest
RK has
catch ya later steel
The first, 1C2, is a broadly neutralizing antibody directed to the gp41-gp120 interface region and neutralizes more than 80% of a panel of 40+ HIV strains.
Conclusions: We conclude that N-glycan-deleted trimer priming followed by heterologous boosting is a successful strategy to elicit bNAbs, validating an epitope-based approach independent of “germline targeting”, and the rabbit immune system that can generate bNAbs using completely different V(D)J building blocks compared to human. The implications of these exciting results are important as we move forward to clinical testing of relevant candidates toward a real-world vaccine.
https://www.liebertpub.com/doi/10.1089/aid.2018.5000.abstracts
Mascola John R
Difference in systemic and mucosal immunoglobulin (Ig)A and IgG concentrations and specificities. Correlations of gp41 Env-specific (a) IgG and (b) IgA in genital secretions vs. plasma during acute HIV-1 infection (AHI). Correlations of (c) plasma and (d) mucosal levels of HIV-1 Env-specific IgG vs. IgA during AHI. Specific activity in mucosal samples is calculated as µg of HIV-specific antibody (Ab) per mg total Ab. Concentrations of anti-gp41 Ab calculated per 2F5 monoclonal Ab equivalents and concentrations of anti-gp120 Abs are calculated as the binding units in the linear range multiplied by the dilution factor divided by total Ab concentration.Download Power Point slide (312 KB)
https://www.researchgate.net/figure/Difference-in-systemic-and-mucosal-immunoglobulin-IgA-and-IgG-concentrations-and_fig6_234089260
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
Georgia D. Tomaras
Juliana McElrath
NIAID HIV Vaccine Trials Network (HVTN) 076, 088, 086, 096, 097, 205 Study TeamsShow fewer authors
https://www.nature.com/articles/s41541-021-00305-8
https://twitter.com/_R_Foundation?ref_src=twsrc%5Etfw%7Ctwcamp%5Eembeddedtimeline%7Ctwterm%5Eprofile%3A_R_Foundation%7Ctwgr%5EeyJ0Zndfc2tlbGV0b25fbG9hZGluZ18xMzM5OCI6eyJidWNrZXQiOiJjdGEiLCJ2ZXJzaW9uIjpudWxsfSwidGZ3X3NwYWNlX2NhcmQiOnsiYnVja2V0Ijoib2ZmIiwidmVyc2lvbiI6bnVsbH0sInRmd19ob3Jpem9uX3R3ZWV0X2VtYmVkXzk1NTUiOnsiYnVja2V0IjoiaHRlIiwidmVyc2lvbiI6bnVsbH0sInRmd19zZW5zaXRpdmVfbWVkaWFfaW50ZXJzdGl0aWFsXzEzOTYzIjp7ImJ1Y2tldCI6ImNvbnRyb2wiLCJ2ZXJzaW9uIjo0fSwidGZ3X2V4cGVyaW1lbnRzX2Nvb2tpZV9leHBpcmF0aW9uIjp7ImJ1Y2tldCI6MTIwOTYwMCwidmVyc2lvbiI6bnVsbH19&ref_url=https%3A%2F%2Fwww.r-project.org%2F
Q&A with Georgia Tomaras, Professor in Surgery and Immunology Researcher
Thursday, February 10, 2022
Our colleagues [who submitted the proposal to the NIH] approached us for working on a component of a global influenza vaccine program, which is to develop standardized methods to evaluate the immune system. We had built a program from HIV and other pathogens where
we are standardizing, qualifying, and validating immune assays that we can use in clinical trials. So when [the grant] was awarded, it was clear that we would need new support for it and the School of Medicine fortunately supported new lab space and equipment.
Georgia Tomaras, PhD, joined Duke in 1998 as a postdoctoral fellow in the Center for AIDS Research to investigate T cells as they relate to human immunodeficiency virus (HIV) immunity. She received her doctor of philosophy
degree from the State University of New York Upstate (SUNY-Upstate) Medical University. Today, Dr. Tomaras holds joint faculty appointments in the Duke Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, and is
Director of the Duke Center for Human Systems Immunology, Immunological Sciences and recently became the Director of the Duke Center for AIDS Research.
Editor's Note: The initial publication of this story incorrectly omitted 'departments of surgery' from the statement regarding Dr. Tomaras's NIH funding acknowledgement.
https://surgery.duke.edu/news/qa-georgia-tomaras-professor-surgery-and-immunology-researcher
Duke Research and Discovery @RTP was born in 2020 when Duke University leased a 273,000 square foot facility in the Parmer RTP research and development campus, former home to pharmaceutical maker GlaxoSmithKline.
https://medschool.duke.edu/research/duke-research-and-discovery-rtp
Yeppers RK cares b/c he brought Ascm here
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162340315
Least we not forget
Odile Launay
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162340236
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162340399
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163926464
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168223025
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163097414
As always the to s & replies
Screw google venture fund & RK's horse
LOL
Gerald Voss
17
TuBerculosis Vaccine Initiative (TBVI), GHF4+6W Lelystad, the Netherlands. Electronic address:
https://pubmed.ncbi.nlm.nih.gov/34489131/
https://pubmed.ncbi.nlm.nih.gov/?term=Voss%20G%5BAuthor%5D&cauthor=true&cauthor_uid=21987658
Dr. Gerald Voss is the Scientific Director of the TuBerculosis Vaccine Initiative (TBVI, Lelystad, The Netherlands) and the Executive Director of SciPeo Sprl, Science & People, a life sciences and coaching consultancy.
Gerald recently served as the Interim Director of the Global HIV Vaccine Enterprise (New York, USA) and led the organization through a merger with the International AIDS Society.
He was previously with GSK vaccines (Rixensart, Belgium), leading the R&D portfolio for Diseases of the Developing World. During his tenure, Dr. Voss established and lead Product Development Partnerships in HIV, TB and malaria with the International AIDS Vaccine Initiative, Aeras, the Malaria Vaccine initiative and the Bill&Melinda Gates Foundation.
Gerald holds a Ph.D. in Biology from Goettingen University (Germany) and received his post-doctoral training at Harvard Medical School (Boston, USA).
https://www.tbvi.eu/team/dr-gerald-voss-2/
https://be.linkedin.com/in/gerald-voss-42597b32?challengeId=AQELiJLTHcVbjQAAAX_MSGWSGusOeAQffmVuP8CCEFcZKdlfsXVG8A63370leeNOqK-DGx0B0swRaYeqtf4ytufsmuAWakjOKg&submissionId=622dcf99-db4a-e016-78ad-94cd78966401
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167840863
Ronnie, instead of being the coach, you should reach out to this guy
LOL
Associated Data Supplementary Materials 2 of 2
Word doc
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Immune-Tech
HIV-1 gp41 MN
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902080/
HIV1 gp41 MN Recombinant Protein
DISCONTINUED
You will be redirected to our replacement product in 1 seconds.
https://www.mybiosource.com/recombinant-protein/hiv1-gp41-mn/536953
w/
HIV-1 gp41 Long Recombinant Protein
Popular Item
https://www.mybiosource.com/recombinant-protein/hiv-1-gp41-long/142607
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated
HIV-1 gp41 MN
1Duke Human Vaccine Institute, 2Department of Medicine, 3Department of Pediatrics, 4Department of Surgery, 5Department of Immunology, and 6Center for Computational Immunology, Duke University School of Medicine, Durham, NC 27710
7The Aaron Diamond AIDS Research Center, New York, NY 10016
8University of Alabama-Birmingham, Birmingham, AL 35294
9University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
10Department of Pathology, Stanford School of Medicine, Stanford, CA 94305
11454 Life Sciences, Branford, CT 06405
12GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
corresponding authorCorresponding author.
CORRESPONDENCE Hua-Xin Liao: ude.ekud@oailh OR Barton F. Haynes: ude.ekud.cm@200enyah
X. Chen, S. Munshaw, G. Tomaras, M.A. Moody, and T.B. Kepler contributed equally to this paper.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201211/
Recombinant HIV-1 MN gp41 Envelope Protein (E.coli)
New
rgp41 HIV-1 MN(E.coli)
https://immunodx.com/products/rgp41-hiv-1-mne-coli
Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
Acknowledgements
WW acknowledges support from the Institut Universitaire de France (IUF), from the European Union's Horizon 2020 research and innovation program under grant agreement No. 681137, H2020 EAVI and the platforms of the Grenoble Instruct-ERIC center (IBS and ISBG; UMS 3518 CNRS-CEA-UGA-EMBL) within the Grenoble Partnership for Structural Biology (PSB). Platform access was supported by FRISBI (ANR-10-INBS-05–02) and GRAL, a project of the University Grenoble Alpes graduate school (Ecoles Universitaires de Recherche) CBH-EUR-GS (ANR-17-EURE-0003). IBS is part of the CEA DRF Interdisciplinary Research Institute of Grenoble (IRIG). JLN acknowledges funding from Spanish MCIU (RTI2018-095624-B-C21; MCIU/AEI/FEDER, UE) and Basque Government (IT1196-19). We thank Miriam Hock and Serafima Guseva for previous contributions to the project, Davide Corti for providing bnAb LN01, the ESRF-EMBL Joint Structural Biology Group for access and support at the ESRF beam lines, J Marquez (EMBL) from the HTX crystallization facility and C Mas and J-B Reiser for assistance on ISBG platforms.
https://elifesciences.org/articles/65005
Davide Corti. Senior Vice President, Antibody Research presso Vir Biotechnology
w/ a Gsk & B&M Gates equity investment
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168092687
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167270024
Rally time yet again so lets hear it for the monkeys lol
Associated Data Supplementary Materials
Word doc
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Immune-Tech
gp41 HxBc2
Duke PPF, Duke Protein Production Facility
NIH AIDS Reagents
Mymetics
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902080/
*Note that the anti-Hu IgA antibody (aHu IgA) from Southern Biotech was evaluated and found to be both cross-reactive with rhesus IgA and demonstrated improved signal as compared to specific anti-RhIgA detection antibodies tested. aRh IgG, anti-rhesus IgG
Headquarters location: Birmingham, AL
https://www.southernbiotech.com/
gp41 (HIV-1/HXBc2)
https://immune-tech.net/product/gp41-hxbc2/
https://www.eenzyme.com/gp41-hiv-1-hxbc2.aspx
https://www.cambridgebiologics.com/product_show.php?id=355
Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys
https://pubmed.ncbi.nlm.nih.gov/11287570/
Harvard
All is welcome steel8000
back to Nova Houston
so catch you later
Our group is a part of it and many other groups, too
a vaccine researcher at Oregon Health & Science University in Portland and co-founder of the biotech company Vir.
Sanders and his colleagues
https://www.iavi.org/iavi-report/vol-25-no-2-2021/what-next-hiv-science-again-at-a-turning-point
I'll say
come on Kempers